# MDxHealth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mdxhealth

- Industry: Biotechnology
- Headquarters: Irvine, US
- Website: www.mdxhealth.com/
- Total disclosed funding: $33M
- Latest round: Series B (Nov 2, 2005)
- Investors on record: 7

## About

Founded in 2003 and based in California, US, MDxHealth, Inc. operates as a provider of molecular diagnostic solutions. In May 2024, Orbimed Advisors provided USD 55 million in debt financing to MDxHealth, Inc. The company can receive an additional USD 45 million that can be drawn under the OrbiMed facility, consisting of a USD 25 million delayed draw term loan and a USD 20 million delayed draw term loan in 2025 and 2026, respectively. As of 2024, the company is led by its CEO, Michael K. McGarrity.

The company’s product suite includes SelectMDx, a urine test that identifies men at risk for aggressive prostate cancer before a biopsy; ConfirmMDx, a tissue test for detecting clinical prostate cancer post-biopsy; and the Genomic Prostate Score (GPS), a genomic assay guiding treatment decisions for localized prostate cancer. In addition, the firm’s ResolveMDx provides personalized therapy options for urinary tract infections. MDxHealth leverages proprietary biomarkers and bioinformatic technologies to develop these diagnostic tests, addressing needs in urologic oncology.

## Funding rounds

- Series B, Nov 2, 2005, $18M — Andera Partners, PolyTechnos Venture-Partners, EQT Life Sciences, ING Belgium, Noshaq, Technowal
- Series A, Mar 12, 2003, $15M — PolyTechnos Venture-Partners, EQT Life Sciences, ING Belgium, Noshaq, Technowal, SIBL Liège-Algerie

## Investors

- PolyTechnos Venture-Partners (https://capitalatlas.ai/funds/polytechnos-venture-partners) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- ING Belgium — Series A, Series B
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A, Series B
- Technowal (https://capitalatlas.ai/funds/technowal) — Series A, Series B
- SIBL Liège-Algerie — Series A
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B